Definitive Healthcare Corp
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
DH$1.19+6.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows provided by (used in) operating activities: | ||
| Net loss | $(12,718) | $(15,972) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation and amortization | 554 | 513 |
| Amortization of intangible assets | 12,130 | 12,431 |
| Amortization of deferred contract costs | 3,692 | 2,860 |
| Equity-based compensation | 15,582 | 11,128 |
| Amortization of debt issuance costs | 176 | 176 |
| Provision for doubtful accounts receivable | 211 | 22 |
| Non-cash impairment charges related to office leases | — | 157 |
| Tax receivable agreement remeasurement | (2,267) | 3,552 |
| Changes in fair value of contingent consideration | 270 | — |
| Deferred income taxes | (847) | (773) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 2,999 | 6,966 |
| Prepaid expenses and other assets | (1,399) | (3,796) |
| Deferred contract costs | (2,699) | (4,021) |
| Contingent consideration | (602) | — |
| Accounts payable, accrued expenses, and other liabilities | (8,231) | (3,855) |
| Deferred revenue | 9,738 | 5,569 |
| Net cash provided by operating activities | 16,589 | 14,957 |
| Cash flows (used in) provided by investing activities: | ||
| Purchases of property, equipment, and other assets | (266) | (1,338) |
| Purchases of short-term investments | (83,826) | (90,252) |
| Maturities of short-term investments | 73,588 | 58,120 |
| Cash paid for acquisitions, net of cash acquired | (13,530) | — |
| Net cash used in investing activities | (24,034) | (33,470) |
| Cash flows used in financing activities: | ||
| Repayments of term loans | (3,438) | (1,719) |
| Taxes paid related to net share settlement of equity awards | (5,806) | (1,530) |
| Payment of contingent consideration | (1,000) | — |
| Payments under tax receivable agreement | (6,950) | (246) |
| Payments of equity offering issuance costs | — | (30) |
| Net cash used in financing activities | (17,194) | (3,525) |
| Net decrease in cash and cash equivalents | (24,639) | (22,038) |
| Effect of exchange rate changes on cash and cash equivalents | (343) | 65 |
| Cash and cash equivalents, beginning of period | 130,976 | 146,934 |
| Cash and cash equivalents, end of period | $105,994 | $124,961 |
| Supplemental cash flow disclosures: | ||
| Cash paid during the period for: | ||
| Interest | $3,642 | $3,475 |
| Income taxes | $— | $79 |
| Acquisitions: | ||
| Net assets acquired, net of cash acquired | $13,675 | $— |
| Working capital adjustment receivable | (145) | — |
| Net cash paid for acquisitions | $13,530 | $— |
| Supplemental disclosure of non-cash investing activities: | ||
| Capital expenditures included in accrued expenses and other liabilities | $— | $333 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.